anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
1. Technical Result Retarding active ingredient release and increase in therapeutic efficiency. 2. Essence An antibiotic polymeric composition comprises one or more suspended, slightly water-soluble antibiotics selected from the groups of aminoglycoside, lincosamide, tetracycline and quinolone antibiotics, possibly an easily water-soluble antibiotic from the groups of aminoglycoside, lincosamide, β-lactam and the tetracycline antibiotics in a homogeneous polymer mixture, consisting of one or more hydrophobic polymers and with addition of one or more organic adjuvants. The use of the composition as a coating on an implant and as a binder for production of antibiotic bodies and laminated plastic. 3. Field of Application Medicine, veterinary.
OPTIRAY can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock. Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock. Most severe reactions develop shortly after the start of the injection (e.g. within 1 to 3 minutes), but delayed reactions may occur. There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities. Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.

Obtain a history of allergy, hypersensitivity, or prior hypersensitivity reactions to iodinated contrast agents. Always have emergency resuscitation equipment and trained personnel available and monitor all patients for hypersensitivity reactions.
The invention discloses a compound 2-(cyclopropylamino)-3-carboxylic acid-4-chloropyridine, which has a molecular formula of C9H9ClN2O2 and a molecular weight of 212.63. The molecular formula is shown in a formula 1. The compound 2-(cyclopropylamino)-3-carboxylic acid-4-chloropyridine can be applied to research on AIDS. The compound in the micromolar concentration has an inhibition effect on non-nucleoside HIV reverse transcriptase. The invention has advantages of available raw materials and simple preparation method. A new drug development pathway is provided for the treatment of AIDS.
PROBLEM TO BE SOLVED: To obtain a new derivative derived from an antibiotic produced by Actinomyces, presenting potent antibacterial action, thus useful as e.g. an antibacterial agent having excellent therapeutic effect on infection. SOLUTION: This compound, a new 10-site nitrogen-contg. substituted methyl 14-membered cyclic macrolide derivative (salt), is expressed by formula I (R is azide or amino), having potent antibacterial action, thus being highly useful as e.g. antibacterial agent having excellent therapeutic effect on infection. This compound is obtained by the following process: formic acid is made to act on sporeamicin of formula II produced by Actinomyces Saccharopolyspora sp. L53-18A to form 9-hydro-10-hydroxysporeamicin which is then reacted with mesitylenesulfonic acid chloride followed by sodium azide to azidate the 10-site of the 9-hydro-10-hydroxysporeamicin followed by, if needed, reducing the resultant azide group into amino group.
PROBLEM TO BE SOLVED: To obtain the subject preparation containing pyridazinone compounds having improved elution and absorbability by formulating pyridazinone compounds with organic acids. SOLUTION: The objective preparation is obtained by formulating a pyridazinone compound (salt) of the formula [R<1> -R<3> are each H and a lower alkyl; X is a halogen, cyano and H; Y is a halogen, trifluoromethyl and H; A is an 1-8C alkylene capable of substituting with a hydroxyl group] with an organic acid. In the above formula, the compound of which R<1> is H is preferable, for example, 4-bromo-6-[3-(4-chlorophenyl)propoxy]-5-(3-pyridylmethyl- amino)-3(2H)-pyridazinone is more preferably illustrated. As the organic acid, citric acid and succinic acid are illustrated. As the does form of the preparation, tablets are favorable. Crystalline cellulose, cornstarch and mannitol are used as preferable vehicles and hydroxypropylmethylcellulose and the like are preferably utilized as binders.  In order to increase the moistureproofing property in tablets, coating with a coating base is preferably performed.
With an estimated 2.5 million HIV-infected persons, India is home to one of the largest populations of HIV-infected persons in the world. Yet, it is estimated that less than 20% of the people living with HIV in India are aware of their status. Andhra Pradesh (AP), situated in south India, is the state with the highest HIV burden in India. Reports from AP suggest usage of voluntary counseling and testing (VCT) is low, especially among high-risk groups. VCT has been shown to have many benefits in addition to diagnosis of HIV infection such as reduction in risk behavior, partner referral, and serving as an entry point to the health care system. Community mobilization and VCT vans have been shown in the past to play a role in increasing utilization of VCT services in various developing countries similar to India. The primary objective of this protocol is to arrive at an effect size of community mobilization alone, and both community mobilization and VCT vans, on the adoption of VCT services in Andhra Pradesh, India. Secondary objectives include identifying barriers to VCT, assessing stigma in the community, and establishing a specimen repository at the YRGCARE infectious disease laboratory in Chennai, India. We will achieve these objectives by conducting a cluster randomized clinical trial with 3 arms: ARM 1: standard of care with pre-existing VCT centers (SVCT); ARM 2: community mobilization in the setting of pre-existing VCT centers (CVCT); ARM 3: community mobilization plus VCT van in addition to the pre-existing VCT centers (MCVCT). The overall study duration will be 6 months from randomization. To our knowledge, this is the first study to examine the role of community mobilization and VCT vans on the adoption of VCT in the Indian context. It will provide us with vital data that will be used to plan a larger powered study to evaluate the effectiveness of these interventions including sites from other parts of India. Additionally, this study will also provide us with important information on barriers to VCT in these communities.
BACKGROUND: Acute aortic dissection (AAD) has high morbidity and a high fatality rate for a cardiovascular disease. Recent studies suggested that the incidence of AAD is increasing. However, the actual incidence and mortality rates of AAD are not well known. This study investigated the current epidemiology of AAD within the Yatsushiro medical jurisdictional area.
METHODS AND RESULTS: A population-based review of patients with AAD was performed in a geographically well-defined area. Data were collected retrospectively from January 2011 to December 2020 for a total of 196 patients with AAD (Stanford Type A, n=126 [64.3%]; Stanford Type B, n=70 [35.7%]). The mean patient age was 74.3 years, and 55.6% (109/196) were women. The crude and age-standardized incidence rates of AAD in our medical jurisdictional area were 13.6 and 11.4 per 100,000 inhabitants per year, respectively. The crude and age-standardized 30-day mortality rates of AAD were 4.9 and 4.0 per 100,000 inhabitants per year, respectively. There were upward tendencies for both the incidence and 30-day mortality rate of AAD with age, with both being significantly higher in patients aged ≥85 years (P<0.001).
CONCLUSIONS: This population-based study detected a higher incidence of AAD than previous studies, but reported a lower incidence of AAD in men than in women. Increasing age was associated with an increased incidence and mortality rate of AAD.
The invention discloses a medicine for treating snake wound. The medicine consists of an internal medicine and an external application medicine. The external application medicine comprises the following drugs by weight: 100 parts of jiangducao, 100 parts of borneol, 100 parts of realgar, 350 parts of zaoqi, 50 parts of Spiranthes sinensis (Pers.) Ames and 100 parts of Hemiboeasubcapitata Clarke. The above drugs are prepared into powders by a conventional pharmaceutical method, then uniformly mixed together according to the above-mentioned parts by weight, and finally blended into a paste by a proper amount of vinegar. The internal medicine comprises the following drugs by weight: 50 parts of jiangducao, 60 parts of Polygonum aviculare, 60 parts of desmodium, 50 parts of the shell of areca nut, 30 parts of dragon's blood, 40 parts of Cortex Phellodendri, 100 parts of licorice, 50 parts of Scutellaria baicalensis, and 30 parts of Coptis chinensis. Each of the drugs is produced into a powder by a conventional pharmaceutical method, and then the drugs are uniformly mixed and compacted into pellets according to the above-mentioned weight ratio. The invention has the advantages of good treatment effect, and low cost of treatment.
PROBLEM TO BE SOLVED: To obtain the subject increasing agent capable of incerasing and developing a brown fatty tissue and thereby carrying out the prophylaxis and improvement in the obesity by including a conjugated linoleic acid as an active ingredient. SOLUTION: This increasing agent is obtained by including a conjugated linoleic acid, preferably 9,11-octadecadienoic acid, 10,11-octadecadienoic acid and a mixture thereof as an active ingredient. The form of the conjugated linoleic acid is preferably a fatty acid, a triglyceride, a sodium salt, a potassium salt, a calcium salt, a phospholipid, a lysophospholipid and a mixture thereof. The above increasing agent can be used as not only a medicine but also an antiobese food. When the above increasing agent is used as a food or a feed, the content of the conjugated linoleic acid in the food or feed is preferably 0.001-100 wt.%. The intake of the conjugated linoleic acid is preferably 0.01-3 wt.% based on the total amount of a diet in any cases of the medicine, food, etc.
As hypotension associated with nitroglycerin overdose is the result of venodilatation and arterial hypovolemia, prudent therapy in this situation should be directed toward increase in central fluid volume. No specific antagonist to the vasodilator effects of nitroglycerin is known. Keep the patient recumbent in a shock position and comfortably warm. Passive movement of the extremities may aid venous return. Intravenous infusion of normal saline or similar fluid may also be necessary. Administer oxygen and artificial ventilation, if necessary. If methemoglobinemia is present, administration of methylene blue (1% solution), 1–2 mg per kilogram of body weight intravenously, may be required unless the patient is known to have G-6-PD deficiency. If an excessive quantity of nitroglycerin has been recently swallowed gastric lavage may be of use.

As epinephrine is ineffective in reversing the severe hypotensive events associated with overdosage, it is not recommended for resuscitation.
The effectiveness of topiramate extended-release capsules as an adjunctive treatment for adults (18 years to 75 years of age) was evaluated in a randomized, international, multi-center, double-blind, parallel-group, placebo-controlled trial in patients with a history of partial-onset seizures, with or without secondary generalization (Study 14).

Patients with partial-onset seizures on a stable dose of 1 to 3 AEDs entered into an 8 week baseline period. Patients who experienced at least 8 partial onset seizures, with or without secondary generalization, and no more than 21 consecutive seizure free days during the 8 week baseline phase were randomly assigned to placebo or topiramate extended-release capsules administered once daily in addition to their concomitant AEDs. Following randomization, 249 patients began the double-blind treatment phase, which consisted of an initial 3 week titration period followed by an 8 week maintenance period. During the titration period, patients received topiramate extended-release capsules or placebo beginning at 50 mg once daily; the dose was increased at weekly intervals by 50 mg once daily, or the placebo equivalent, until a final dose of 200 mg once daily was achieved. Patients then entered the maintenance period at the assigned dose of 200 mg once daily, or its placebo equivalent.

The percent reduction in the frequency of partial-onset seizure, baseline period compared to the treatment phase, was the primary endpoint. Data was analyzed by the Wilcoxon rank-sum test, with the criteria of statistical significance of p < 0.05. The results of the analysis are presented in Table 15. The median percent reduction in seizure rate was 39.5% in patients taking topiramate extended-release capsules (N=124) and 21.7% in patients taking placebo (N=125). This difference was statistically significant. 

Figure 2 shows the change from baseline during titration plus maintenance (11 weeks) in partial-onset seizure frequency by category for patients treated with topiramate extended-release capsules and placebo. Patients in whom the seizure frequency increased are shown as "worse." Patients in whom the seizure frequency decreased are shown in four categories of reduction in seizure frequency.

Figure 2

Proportion of Patients by Category of Seizure Response to Topiramate Extended-Release Capsules and Placebo
In the study, 124 patients will randomly assigned to acupressure/experimental group and control group. To the acupressure/experimental group (n = 62), an average of 15 minutes will be applied to the LI4 (liver, between thumb and forefinger), P6 (pericardium, three fingers above the wrist) and LI 11 is located the area where the elbow bend. On the other hand, no other intervention will be applied to the control group other than routine treatment and nursing care. The primary outcome of the research is the effect of acupressure on the pain of patients. The secondary outcome of the study is to determine the effect of acupressure on the hemodynamic variables. The pain and hemodynamic variables will be collected before, immediately after the application, 10th, 20th and 30th minutes after the application. Data will also be collected from the control group at the same time.
The median sacral artery (MSA) is the single unpaired dorsal branch of the abdominal aorta. The present case describes the relatively unusual origin of the median sacral artery in common with the fourth pair of lumbar arteries via a common trunk in a 74-year-old males' cadaver. Unusual common trunk is prone for iatrogenic injury in surgeries of the lumbar and pelvic region. Owing to the deep seated nature of MSA close to the periosteum of lumbar vertebrae and sacrum, detection of accidental rupture of MSA and ligation thereof becomes a difficult task. MSA is also increasingly being utilized for intra-arterial embolization of pelvic tumours. The proximal portion of the common origin may at times undergo cone shaped dilatation which is referred to as infundibulum or infundibular dilatation and can also transform into aneurysm later. Knowledge of this variation is imperative for spine and pelvic surgeons to avoid unwanted complications.
Cognitive Behavioral Therapy (CBT) is the most widely used non-pharmacologic intervention for chronic pain and a version of CBT specifically addressing chronic pain (CBT-CP) has been developed for use in VA with Veterans. Fundamentally, CBT is an approach that seeks to ameliorate dysfunctional relationships between an individual's thoughts, feelings, and behaviors to improve functioning and quality of life. At our site, the CBT-CP format has been adapted for clinical use (i.e., as part of usual clinical care) to 8 sessions in a video group format, while retaining all essential elements.
Orofacial muscle defect due to congenital anomalies, tumour ablation or traumatic accident that exceeds endogenous regeneration capacity may lead to sustained deficits in masticatory function and nutrition intake. Functional recovery has always been the goal of muscle tissue repair, but currently, there is no suitable model for quantitative analyses of either functional consequences or treatment efficacy of orofacial muscle defect. This study proposed a critical size volumetric muscle loss (VML) model in mouse masseter with impaired mastication on nutrition. Full-thickness VML defects in diameter of 1.0, 1.5, 2.0 and 3.0 mm were generated in the centre of the mouse masseter using a biopsy punch to determine the critical size for functional impairment. In the VML region, myogenesis was dampened but fibrogenesis was activated, as long with a reduction in the density of the neuromuscular junction and an increase in vascular density. Accordingly, persistent fibrosis was observed in the centre region of VML in all diameters. The 2.0 mm diameter was the critical threshold to masticatory function impairment after VML in the masseter. VML of 3.0 mm diameter led to a significant impact on nutrition intake and body weight gain. Autologous muscle graft effectively relieved the fibrosis and functional deficit after VML injury in the masseter. This model serves as a reliable tool in studying functional recovery strategies for orofacial muscle defects.
1530367 Coated bath crown SUMITOMO CHEMICAL CO Ltd 21 July 1976 [21 July 1975 22 July 1975] 30454/76 Heading B2E An artificial bath crown is prepared by thermally spraying, e.g. by plasma spraying, a bonding agent, e.g. Mo, Ta, Nb, Ni-Cr-Al alloy or Ni-Al alloy on to a base of a dentally acceptable metal. A layer of a ceramic is thermally sprayed on to the bonding layer and a dentally acceptable porcelain layer is formed and fused as the outermost layer. The ceramic may be ZrO 2  or Al 2 O 3 . The bonding layer may be sprayed with a mixture of bonding agent and ceramic before applying the ceramic layer.
Prograf can cause nephrotoxicity, particularly when used in high doses. Nephrotoxicity was reported in approximately 52% of kidney transplantation patients and in 40% and 36% of liver transplantation patients receiving Prograf in the U.S. and European randomized trials, respectively, and in 59% of heart transplantation patients in a European randomized trial (see ADVERSE REACTIONS). Use of Prograf with sirolimus in heart transplantation patients in a US study was associated with increased risk of renal function impairment, and is not recommended (See CLINICAL STUDIES). More overt nephrotoxicity is seen early after transplantation, characterized by increasing serum creatinine and a decrease in urine output. Patients with impaired renal function should be monitored closely as the dosage of Prograf may need to be reduced. In patients with persistent elevations of serum creatinine who are unresponsive to dosage adjustments, consideration should be given to changing to another immunosuppressive therapy. Care should be taken in using tacrolimus with other nephrotoxic drugs. In particular, to avoid excess nephrotoxicity, Prograf should not be used simultaneously with cyclosporine. Prograf or cyclosporine should be discontinued at least 24 hours prior to initiating the other. In the presence of elevated Prograf or cyclosporine concentrations, dosing with the other drug usually should be further delayed.
Invention applies to the medicine and pharmaceutical industry. The invention aims to increase the efficiency of treatment. The herb mixture consists of the following components in g: flax seeds (Seminis Lini) - 40, milfoil grass (Herba Millefolii) - 20, motherwort grass (Herba Leonuri) - 10, marigold flowers (Flores Calendulae) - 15. The mixtures components - motherwort grass, milfoil grass and marigold flowers are pulverised by a hammer crusher and the fine particles sifted. Components are mixed in a drum mixer until the mixture becomes homogeneous. For the treatment, the herb mixture infusion is used. Consuming the proposed herb mixture infusion, stomach acidity, function and alimentary canal are normalized and closure of the ulcer is noticeable within a week.
The invention provides a sustained-release injection containing nitrosourea drug (galamustine), which contains sustained-release microspheres and solvents. The sustained-release microspheres each comprise an anticancer-active component selected from nitrosourea drugs (such as nimustine and carmustine) and/or topoisomerase inhibitors, and a sustained-release agent. The solvents are common solvents or special solvents containing suspending agent. The viscosity of the suspending agent ranges from 100cp to 3000cp (at a temperature ranging from 20 DEG C to 30 DEG C). The suspending agent is selected from sodium carboxymethylcellulose and the like. The sustained-release agent is selected from p(LAEG-EOP) or p(DAPG-EOP) or other polyphosphate ester copolymers, or copolymer or blend of polyphosphate ester and PLA, polifeprosan, PLGA or poly(erucidic acid dipolymer-sebacic acid). The topoisomerase inhibitor is selected from camptothecin, hydroxycamptothecine, topotecan, lartotecan, irinotecan, etoposide or teniposide. The anticancer composition is also available in the dosage form of sustained-release implant, can retain the effective drug concentration for more than 60 days after intratumoral or local injection or implantation, can obviously reduce the systemic reaction to the drug, and can selectively enhance the curative effect of non-operative treatments such as radiotherapy and chemotherapy.
A method and system for forming a pharmaceutical dosage form within a portion of a blister package. The method comprises the step of providing a blister package for a dosage form having a recess. A predetermined amount of a drug-containing powder material comprising drug-containing particles is deposited as a substantially uniform powder layer within the recess. A binding liquid is then deposited in a pattern on the powder layer within the recess to bind the particles of the powder layer and form an incrementally wetted layer. Excess solvent in the bonding material may be removed to form an incremental bonding layer. These steps are repeated sequentially at least one or more times to form a pharmaceutical dosage form within the blister package.
Participants in the training group will receive a 13-week training program delivered via videoconference. The program includes 13 modules delivered via videoconference over the course of the 3-month program in weekly 60- to 90-minute sessions. Participants will receive a training manual, be shown filmed vignettes, and will have access to a chatroom and an online resource centre.